Policy and Advocacy News
Policy and Advocacy News
-
From HIV to Global Cancer Prevention: A New Chapter in Global Health Financing
The Global Cancer Financing Platform is an ambitious new effort to mobilize at least $1 billion by 2030 focused on “stage shifting” or catching cancers earlier. The Platform will raise funds through innovative financing approaches and is based on HIV initiatives such as PEPFAR and the Global Fund
-
When Grants End, So Do Scientific Breakthroughs
New analysis from amfAR’s Public Policy Office assesses the human cost of terminated federal research grants focused on cancer.
-
24 Hours to Save AIDS Research
A global campaign—24 Hours to Save AIDS Research—draws on expertise of researchers and advocates to call for sustained U.S. funding for HIV research.
-
Community-Led Health Programs Benefit People Impacted by HIV
New amfAR-funded study—the SCOPE report—shows how local experts are essential to Global Fund-supported healthcare delivery.
-
Title X Restrictions Harm the U.S. HIV Response
New amfAR analysis of Title X funding restrictions shows that ending the HIV epidemic is jeopardized when federal limits are placed on family planning services.
-
Progress on HIV—Derailed
The latest UNAIDS report shows advances in the global HIV response but warns funding cuts are creating a crisis for millions of people impacted by HIV.
-
FDA Approves Lenacapavir for HIV Pre-Exposure Prophylaxis
The FDA-approved lenacapavir for PrEP holds the potential to dramatically reduce HIV infections with its adherence-friendly twice-annual injection.
-
amfAR Report Details How PEPFAR Support Allowed Governments to Strengthen Health Systems
Domestic healthcare spending and capacity growth in PEPFAR countries exceeds non-PEPFAR countries, as detailed by amfAR, The Foundation for AIDS Research.
-
Cuts to the CDC’s Division of HIV Prevention Will Lead to Dramatic Rise in Infections, Deaths, and Costs
Without funding, there will be a loss of momentum in reducing HIV cases, and the nation’s epidemic will worsen significantly.
-
President Trump’s HIV Plan Is Too Valuable to Lose
amfAR analyses show states that implemented EHE would avert significantly more HIV treatment costs by 2030.
-
The Hidden Cost of Capping NIH Indirect Costs: How Students Pay the Price
Revision of federal grant policy for health research would deal economic blow to roughly 600 U.S. universities and university systems
-
The Best Investment You Didn’t Know You Made: How NIH Funding Fuels Innovation and Economic Growth
Continued investment in the NIH is essential to fighting current and emerging health threats and to ensuring the U.S. remains a global leader in medical innovation.
-
Assessing the Impact of the PEPFAR Stop Work Order
An analysis by amfAR and other advocacy groups shows that the Trump Administration’s HIV funding freeze is reversing hard-won progress toward ending AIDS.
-
Supporting Health Advocacy from the Ground Up
In collaboration with the group Data, Et cetera, amfAR’s public policy office has published a new issue brief that examines the Global Fund’s efforts to strengthen community-focused HIV/AIDS programming.
-
Science, Public Health, and Advocacy Converge at amfAR + M•A•C Event
To commemorate World AIDS Day, amfAR and M•A•C Cosmetics hosted a panel discussion that covered HIV cure research, advocacy, and public health.